Genomas

Bringing Personalized Medicine to Clinical Practices

Genomas

Genomas delivers Personalized Medicine to modern clinical practices. Genomas develops revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. These systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.

Key Features

  • Provides DNA-Guided medicine for clinical practices
  • Personalizes the prescription of drugs
  • Eliminates trial-and-error prescription
  • Enables physicians to treat with unprecedented precision
  • Avoids significant drug side effects while improving efficacy and enhancing patient compliance

Refining Patient Prescriptions

PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.

Predicting Treatment Side Effects

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient.

Suite of Solutions

Hilomet Phyziotypetm™ System

Assisting providers with DNA-based assessment tools to guide their neuro-psychiatric and cardio-metabolic drug choices for patients evidencing treatment resistance or drug intolerance.

More Info

Pims Phyziotypetm™ System

Providing physicians with the patient's risk profile for weight- and lipid-related side effects for the major atypical antipsychotics (aaps), olanzapine, quetiapine, and risperidone.

More Info

Sinm Phyziotypetm™ System

Providing physicians with DNA-guided efficacy predictions for aggressive lipid lowering and risk profiles for neuromuscular side effects of atorvastatin, simvastatin, and rosuvastatin.

More Info

GLIM Phyziotypetm™ System

The GLIM Phyziotype system is currently in development. It will consist of 4 tests predicting blood glucose lowering efficacy (hba1c), weight gain or loss, risk of edema, and likelihood of severe vomiting in response to tzd and incretin medications on a class-wide and drug-specific basis.

More Info

About

Rennova Health offers a complete solution, with faster turnaround times and more reliable and accurate results, in a manner that is safe, secure and HIPAA-compliant in all respects.

Learn More

Solutions

Learn more about our proprietary suite of vital, integrated solutions.

View Solutions